Cargando…
The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia
Aberrant activation of the PI3K/Akt/mTOR pathway is a common feature of acute myeloid leukemia (AML) patients contributing to chemoresistance, disease progression and unfavourable outcome. Therefore, inhibition of this pathway may represent a potential therapeutic approach in AML. The aim of this st...
Autores principales: | Allegretti, Matteo, Ricciardi, Maria Rosaria, Licchetta, Roberto, Mirabilii, Simone, Orecchioni, Stefania, Reggiani, Francesca, Talarico, Giovanna, Foà, Roberto, Bertolini, Francesco, Amadori, Sergio, Torrisi, Maria Rosaria, Tafuri, Agostino |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682184/ https://www.ncbi.nlm.nih.gov/pubmed/26674543 http://dx.doi.org/10.1038/srep18137 |
Ejemplares similares
-
Erratum: The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia
por: Allegretti, Matteo, et al.
Publicado: (2016) -
BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma
por: Speranza, Maria-Carmela, et al.
Publicado: (2016) -
Inhibitory effect of NVP-BKM120 on cholangiocarcinoma cell growth
por: Padthaisong, Sureerat, et al.
Publicado: (2018) -
NVP-BKM120 inhibits colon cancer growth via FoxO3a-dependent PUMA induction
por: Yang, Shida, et al.
Publicado: (2017) -
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients
por: Ricciardi, Maria Rosaria, et al.
Publicado: (2018)